Mesa Biotech obtained FDA 510(k) clearance and a Clinical Laboratory Improvements Amendments waiver for its Accula Flu A/Flu B test.

The disposable point-of-care test cassette is the first one to receive FDA clearance for use on the company’s polymerase chain reaction Accula testing platform, featuring a portable dock. It can provide test results in about 30 minutes using samples from nasal swabs.

The San Diego-based molecular diagnostic company received a CE Mark for the assay-specific product just last month.